

Open Peer Review on Qeios

## PI3K Inhibitor GDC-0941 Bismesylate

National Cancer Institute

## Source

National Cancer Institute. <u>PI3K Inhibitor GDC-0941 Bismesylate</u>. NCI Thesaurus. Code C82380.

The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway; inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations may result. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Qeios ID: UO7QQ5 · https://doi.org/10.32388/UO7QQ5